Sources: 
Biostate AI, founded in 2023 by David Zhang and Ashwin Gopinath, has raised $12 million in Series A funding led by Accel. The company aims to expand its RNA sequencing services, which are crucial for integrated precision medicine.
The startup has processed over
10,000 RNAseq samples from more than
150 partners and clients since launching its commercial offering two quarters ago. With this new funding, Biostate AI plans to enhance its customer base through over
100 pilot projects across various disease indications, including leukemia and multiple sclerosis.
Gopinath's personal connection to personalized medicine, stemming from his wife's leukemia diagnosis, drives the company's mission to build generative AI models that predict drug responses using RNA sequencing data. The technology is projected to generate between
$60 billion to $110 billion annually in economic value for the pharmaceutical and medical-product industries, highlighting its potential impact.
Biostate AI has raised over
$20 million to date, positioning itself as a key player in the evolving landscape of precision medicine and AI-driven healthcare solutions.
Sources: Biostate AI, an AI and RNA sequencing firm, has secured $12 million in Series A funding from Accel to enhance its RNA sequencing services for precision medicine. Founded in 2023, the company has processed over 10,000 RNAseq samples and aims to revolutionize drug response predictions.
